171 related articles for article (PubMed ID: 36229087)
1. Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy.
Ascher SB; de Lemos JA; Lee M; Wu E; Soliman EZ; Neeland IJ; Kitzman DW; Ballantyne CM; Nambi V; Killeen AA; Ix JH; Shlipak MG; Berry JD
J Am Coll Cardiol; 2022 Oct; 80(16):1516-1525. PubMed ID: 36229087
[TBL] [Abstract][Full Text] [Related]
2. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
[TBL] [Abstract][Full Text] [Related]
3. Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial.
Berry JD; Nambi V; Ambrosius WT; Chen H; Killeen AA; Taylor A; Toto RD; Soliman EZ; McEvoy JW; Pandey A; Joshi PH; Blankenberg S; Kitzman DW; Ballantyne CM; de Lemos JA
JAMA Cardiol; 2021 Dec; 6(12):1397-1405. PubMed ID: 34468696
[TBL] [Abstract][Full Text] [Related]
4. Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT.
Berry JD; Chen H; Nambi V; Ambrosius WT; Ascher SB; Shlipak MG; Ix JH; Gupta R; Killeen A; Toto RD; Kitzman DW; Ballantyne CM; de Lemos JA
Circulation; 2023 Jan; 147(4):310-323. PubMed ID: 36533535
[TBL] [Abstract][Full Text] [Related]
5. "Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis).
Peters MN; Seliger SL; Christenson RH; Hong-Zohlman SN; Daniels LB; Lima JAC; de Lemos JA; Neeland IJ; deFilippi CR
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437599
[TBL] [Abstract][Full Text] [Related]
6. Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy.
Ahmad MI; Kazibwe R; Soliman MZ; Singh S; Chen LY; Soliman EZ
Am J Cardiol; 2023 Dec; 208():75-82. PubMed ID: 37820550
[TBL] [Abstract][Full Text] [Related]
7. Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study).
Seliger SL; de Lemos J; Neeland IJ; Christenson R; Gottdiener J; Drazner MH; Berry J; Sorkin J; deFilippi C
JACC Heart Fail; 2015 Jun; 3(6):445-455. PubMed ID: 25982111
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.
Neeland IJ; Drazner MH; Berry JD; Ayers CR; deFilippi C; Seliger SL; Nambi V; McGuire DK; Omland T; de Lemos JA
J Am Coll Cardiol; 2013 Jan; 61(2):187-95. PubMed ID: 23219305
[TBL] [Abstract][Full Text] [Related]
9. Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial.
Deng Y; Liu W; Yang X; Guo Z; Zhang J; Huang R; Yang X; Yu C; Yu J; Cai J;
Hypertension; 2023 Sep; 80(9):1834-1842. PubMed ID: 37259845
[TBL] [Abstract][Full Text] [Related]
10. Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study.
Lewis AA; Ayers CR; Selvin E; Neeland I; Ballantyne CM; Nambi V; Pandey A; Powell-Wiley TM; Drazner MH; Carnethon MR; Berry JD; Seliger SL; DeFilippi CR; de Lemos JA
Circulation; 2020 Mar; 141(12):957-967. PubMed ID: 31931608
[TBL] [Abstract][Full Text] [Related]
11. Achieving a Systolic Blood Pressure Below 130 mmHg Reduces the Incidence of Cardiovascular Events in Hypertensive Patients with Echocardiographic Left Ventricular Hypertrophy.
Lembo M; Trimarco V; Izzo R; Manzi MV; Rozza F; Gallo P; Morisco C; Bardi L; Esposito G; Forzano I; Santulli G; Trimarco B
J Pharmacol Exp Ther; 2024 Jun; 390(1):4-10. PubMed ID: 38135511
[No Abstract] [Full Text] [Related]
12. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Johnson K; Oparil S; Davis BR; Tereshchenko LG
J Am Heart Assoc; 2019 Apr; 8(8):e011961. PubMed ID: 30943832
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis.
Pandey A; Patel KV; Vongpatanasin W; Ayers C; Berry JD; Mentz RJ; Blaha MJ; McEvoy JW; Muntner P; Vaduganathan M; Correa A; Butler J; Shimbo D; Nambi V; deFilippi C; Seliger SL; Ballantyne CM; Selvin E; de Lemos JA; Joshi PH
Circulation; 2019 Dec; 140(25):2076-2088. PubMed ID: 31707797
[TBL] [Abstract][Full Text] [Related]
14. Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction.
Hieda M; Sarma S; Hearon CM; Dias KA; Martinez J; Samels M; Everding B; Palmer D; Livingston S; Morris M; Howden E; Levine BD
Circulation; 2020 Jan; 141(2):115-123. PubMed ID: 31865771
[TBL] [Abstract][Full Text] [Related]
15. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: a meta-analysis of randomized trials.
Hu J; Zhou Y
Blood Press; 2023 Dec; 32(1):2242501. PubMed ID: 37652401
[TBL] [Abstract][Full Text] [Related]
16. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial.
Soliman EZ; Byington RP; Bigger JT; Evans G; Okin PM; Goff DC; Chen H
Hypertension; 2015 Dec; 66(6):1123-9. PubMed ID: 26459421
[TBL] [Abstract][Full Text] [Related]
17. Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg.
Heimark S; Mehlum MH; Mancia G; Søraas CL; Liestøl K; Wachtell K; Larstorp AC; Rostrup M; Mariampillai JE; Kjeldsen SE; Julius S; Weber MA
Hypertension; 2023 Aug; 80(8):1739-1748. PubMed ID: 37350267
[TBL] [Abstract][Full Text] [Related]
18. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial.
Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
[TBL] [Abstract][Full Text] [Related]
20. On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy.
Lee HH; Lee H; Cho SMJ; Kim DW; Park S; Kim HC
J Am Coll Cardiol; 2021 Oct; 78(15):1485-1495. PubMed ID: 34620404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
